Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer

Figure 5

The confirmation of correlation between MRPL13 expression and prognosis. (a–d) highly expressed MRPL13 displayed shorter (a) RFS, (b) PPS, (c) OS, and (d) DMFS time. (e–h) Subtype analysis showed that (e) luminal A, (g) luminal B, (h) HER2-positive, and (f) TNBC patients with high levels of MRPL13 expression had shorter RFS time.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)